iShares Micro-Cap

Latest iShares Micro-Cap News and Updates

  • uploads///EPS
    Earnings Report

    What Do Analysts Expect from Flotek’s 4Q16 Earnings?

    In 4Q16, analysts expect Flotek Industries (FTK) to post an adjusted loss per share of ~$0.04.

    By Alex Chamberlin
  • uploads///Broker Recommendations
    Miscellaneous

    Wall Street Analysts’ Forecasts for Flotek Industries

    On May 3, 2017, after Flotek Industries’ 1Q17 earnings were released, all of the sell-side analysts tracking Flotek Industries rated it as a “buy.”

    By Alex Chamberlin
  • uploads///Upstream capex and EBITDA
    Miscellaneous

    How Flotek Could React to Upstream Operators’ Capex and the Rig Count

    From 1Q16 to 1Q17, Flotek’s EBITDA margin shrank to 3.3% from 4.1%. FTK’s EBITDA margin has been 1.7%, on average, for the past five quarters.

    By Alex Chamberlin
  • uploads///EPS
    Materials

    What Analysts Expect from Flotek Industries’ 3Q17 Earnings

    In 3Q17, analysts expect Flotek Industries (FTK) to report adjusted earnings per share of $0.02. Wall Street expects FTK’s revenues to rise 1% over 2Q17 to $86.2 million.

    By Alex Chamberlin
  • uploads///EPS Top
    Company & Industry Overviews

    Best Oilfield Services Stocks for 1Q17 by EPS Growth

    Among our group of OFS companies, analysts expect Halliburton (HAL) to see the highest rise in adjusted EPS in 1Q17.

    By Alex Chamberlin
  • uploads///Upstream capexx and EBITDA
    Materials

    How Rig Count and Upstream Operator Capex Affected FTK

    From 2Q16 to 2Q17, Flotek Industries’ (FTK) EBITDA margin (or EBITDA as a percentage of revenues) improved to 2.3% from 0.7%.

    By Alex Chamberlin
  • uploads///Ignyta Pipeline
    Company & Industry Overviews

    Ignyta’s Drug Pipeline

    Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.

    By Kenneth Smith
  • uploads///Chart Insys
    Company & Industry Overviews

    A Closer Look at Insys Therapeutics’ Performance Year-to-Date

    Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.

    By Mike Benson
  • uploads///Cara Analysts reco
    Company & Industry Overviews

    Analysts’ Recommendations for Cara Therapeutics in January 2018

    Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus.

    By Kenneth Smith
  • uploads///ATRA focus Therapies
    Company & Industry Overviews

    Inside Atara Biotherapeutics’ Promising Product Pipeline

    Atara’s most advanced T-cell therapy in development is its ATA129, which is under development for the treatment of cancer patients with Epstein Barr virus.

    By Kenneth Smith
  • uploads///Hepatitis B virus life cycle
    Company & Industry Overviews

    Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases

    ARO-HBV is Arrowhead Pharmaceuticals’ (ARWR) investigational drug candidate for treating chronic hepatitis B infection.

    By Kenneth Smith
  • uploads///SI
    Materials

    A Look at Short Interest in Flotek Industries on October 16

    Short interest in Flotek Industries (FTK) as a percentage of its float was 20.3% on October 16, 2017, compared to 22.8% on June 30, 2017.

    By Alex Chamberlin
  • uploads///IV
    Energy & Utilities

    Basic Energy Services’ Next-7-Day Stock Price Forecast

    Since 2Q17 earnings were announced on July 27, Basic Energy Services’ implied volatility (or IV) has risen from 62% to the current level.

    By Alex Chamberlin
  • uploads///Broker Recommendations
    Materials

    Wall Street Analysts’ Recommendations for Flotek Industries

    On August 10, 2017, all of the sell-side analysts tracking Flotek Industries rated it as a “buy.” None of the analysts rated Flotek as a “hold” or “sell.”

    By Alex Chamberlin
  • uploads///FCF
    Materials

    How Flotek Industries’ 2017 Capex Plans Changed

    Flotek Industries’ (FTK) cash from operating activities (or CFO) remained negative in 2Q17, continuing with a negative cash flow trend in 1Q17.

    By Alex Chamberlin
  • uploads///FCF
    Miscellaneous

    Inside Flotek Industries’ New 2017 Capex Plan

    Flotek’s (FTK) CFO (cash from operating activities) was negative in 1Q17, after being positive for three quarters. FTK’s CFO was -$2.5 million in 1Q17.

    By Alex Chamberlin
  • uploads///SI
    Miscellaneous

    What Was the Short Interest in Basic Energy Services on May 8?

    Short interest in Basic Energy Services (BAS) as a percentage of its float is 4.4% as of May 8 compared to 4.6% as of March 31, 2017.

    By Alex Chamberlin
  • uploads///Reemergence
    Miscellaneous

    Can Basic Energy Grow after Emerging from Bankruptcy?

    On October 25, 2016, Basic Energy Services (BAS) filed for bankruptcy after a persistently weak performance in an energy market that was gripped by pricing weakness.

    By Alex Chamberlin
  • uploads///Stock Price and Outlook
    Miscellaneous

    Analyzing Basic Energy Services’ Future Drivers

    Basic Energy Services’ (BAS) management expects increased rig utilization and better pricing to result in a higher operating margin in 1Q17.

    By Alex Chamberlin
  • uploads///FCF
    Company & Industry Overviews

    Flotek Industries’ Capex: Impact of a Credit Facility Agreement

    In this article, we’ll analyze how Flotek Industries’ (FTK) operating cash flows trended over the past few quarters.

    By Alex Chamberlin
  • uploads///Broker Recommendations
    Earnings Report

    What Are Wall Street’s Forecasts for Flotek before 4Q16 Earnings?

    On January 13, all the analysts tracking Flotek Industries rated it a “buy” or some equivalent.

    By Alex Chamberlin
  • uploads///Upstream Capex and EBITDA
    Earnings Report

    Will Upstream Operators’ Capex Impact Tidewater’s Margin?

    In the past few years, some major US upstream and integrated companies reduced their capex following the sharp fall in crude oil prices.

    By Alex Chamberlin
  • uploads///Segment Revenue
    Earnings Report

    What Are Tidewater’s Growth Drivers?

    From April 1 to September 30 of fiscal 2017, Tidewater’s (TDW) revenues fell 46% compared to the same period in fiscal 2016.

    By Alex Chamberlin
  • uploads///IV
    Earnings Report

    What Does Flotek Industries’ Implied Volatility Suggest?

    On January 13, 2017, Flotek Industries (FTK) had an implied volatility of 81%.

    By Alex Chamberlin
  • uploads///Capex and Margin
    Earnings Report

    Will Upstream Operators’ Capex Affect Flotek’s 4Q16 Margin?

    In the past couple of years, some of the major US upstream and integrated companies have reduced capital expenditure as a result of crude oil’s sharp decline.

    By Alex Chamberlin
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.